On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
A new Queensland study from Son Nghiem, Pete Lazzarini, Lauren Ward and colleagues in Diabetic Medicine finds that investing in earlier access to diabetic foot services returns nearly $8 for every $1 spent — with lower costs, fewer hospitalisations, and better quality of life.
A cost-effectiveness analysis of the DIAFOS trial shows that in-shoe plantar pressure-guided custom footwear saves over €8,000 per ulcer prevented — and adherent patients push the probability of cost-effectiveness to 94%. The economic case for prevention just got stronger.
A recent study published in Therapeutic Advances in Endocrinology and Metabolism compares two approaches for managing diabetic foot with osteomyelitis: amputation versus circular external fixation (CEF). The research highlights a pressing issue in diabetes care, as Charcot foot—a severe complication involving infected ulcers—often leads to amputation, with five-year mortality rates reaching as high as 70%.... Continue Reading →
Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment Data continue to support the use of amnion-chorion allografts. These additional data seem to suggest a relative risk reduction for hospital admission, readmission, emergency department visits, low and high level amputation. William H Tettelbach 1 2 3 4 5 6, David G Armstrong 7 8, Thomas J Chang 9, Julie L De Jong 1, Paul M... Continue Reading →
